Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital

被引:2
|
作者
Bauduer, F. [1 ,2 ,3 ]
Recanzone, H. [2 ]
机构
[1] Ctr Hosp Cote Basque, Serv Hematol, 13 Ave Jacques Loeb, F-64100 Bayonne, France
[2] Ctr Hosp Cote Basque, Unite Hemovigilance, Bayonne, France
[3] Univ Bordeaux, Coll Sci Sante, Bordeaux, France
关键词
Iron overload; Myelodysplastic syndromes; RBC transfusion; Iron chelation; CHELATION-THERAPY; RISK MDS; SURVIVAL; IMPACT;
D O I
10.1016/j.tracli.2020.05.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We retrospectively assessed the characteristics of 165 MDS patients from our institution having received at least 20 RBC units. In the vast majority of them various comorbidities (range: 1-6 per patient) were registered including mainly cardiovascular disorders. Serum ferritin was over 1000 mu g/L in about half of tested individuals. A chelator agent was initiated in 43.6% of patients (mainly low-risk MDS). Transformation in AML occurred in 46 cases (27.8%). Overall, 112 patients died during follow up. The cause of death was documented in 65 cases and included mainly MDS or AML resistance to therapy. There was a context of bacterial or fungal-related sepsis in 35.3% of cases. We noticed a correlation between survival and number of RBC transfusions. Median OS from the 20th RBC unit was significantly prolonged among the chelated subgroup. Consequences of transfusional iron overload and chelation need to be clarified in MDS patients. (C) 2020 Societe francaise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:128 / 132
页数:5
相关论文
共 50 条